Aptose Biosciences (NASDAQ:APTO) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note released on Friday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $2.00 price objective on shares of Aptose Biosciences in a research report on Friday, January 10th.

Aptose Biosciences Trading Up 3.7 %

APTO stock opened at $0.21 on Friday. The firm has a 50-day moving average of $0.22 and a two-hundred day moving average of $0.36. Aptose Biosciences has a 12 month low of $0.13 and a 12 month high of $2.20. The company has a market cap of $12.82 million, a price-to-earnings ratio of -0.07 and a beta of 0.87.

Hedge Funds Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp grew its position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 401,750 shares of the biotechnology company’s stock after buying an additional 167,282 shares during the quarter. Sigma Planning Corp owned 2.22% of Aptose Biosciences worth $165,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.